Lenvatinib Approved in Europe for Frontline HCC

August 23, 2018 – The European Commission has approved lenvatinib as a first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma (HCC). The approval was based on data from the phase III REFLECT trial, which were published in February 2018 in the Lancet. In the trial, the multikinase inhibitor lenvatinib showed noninferiority to the established first-line standard of care, sorafenib. The median overall survival (OS) by … (leggi tutto)